November 21 coronavirus news

By Ben Westcott, Adam Renton, Rob Picheta and Meg Wagner, CNN

Updated 0025 GMT (0825 HKT) November 23, 2020
1 Post
Sort byDropdown arrow
7:51 p.m. ET, November 20, 2020

Pfizer and BioNTech apply for FDA emergency use authorization for coronavirus vaccine

From CNN's Jamie Gumbrecht

Pfizer and BioNTech on Friday submitted to the US Food and Drug Administration for emergency use authorization for their coronavirus vaccine candidate.

This is the first coronavirus vaccine to seek regulatory clearance in the United States.

"It is with great pride and joy and even a little relief that I can say that our request for emergency use authorization for our Covid-19 vaccine is now in the FDA's hands," Pfizer CEO Albert Bourla said in a video shared on Friday. "This is a historic day, a historic day for science and for all of us. It took just 248 days to get from the day we announced our plans to collaborate with BioNTech to our FDA submission day.
"We have operated at extraordinary speed in our clinical development program, from concept to regulatory filing, while always maintaining our focus on safety."

The vaccine, known as BNT162b2, could potentially be available for use in high-risk populations in the United States by the middle to end of December, Pfizer and BioNTech said in a statement earlier Friday. The vaccine requires two doses a few weeks apart, and protection is achieved 28 days after the first shot.

The submission to the FDA is based on results from the Phase 3 clinical trial of Pfizer's vaccine, which began in the United States on July 27 and enrolled more than 43,000 volunteers.

The final analysis from the trial found the coronavirus vaccine was 95% effective in preventing infections, even in older adults, and caused no serious safety concerns, Pfizer and BioNTech said this week. The submission also includes safety data on about 100 children ages 12 to 15.

Read the full story: